1. DSpace-CRIS UAEMEX
  2. Interoperabilidad Repositorio Nacional
  3. Producción
Please use this identifier to cite or link to this item: http://ri.uaemex.mx/handle20.500.11799/105353
DC FieldValueLanguage
dc.creatorBRENDA VIANEY GIBBENS BANDALA-
dc.creatorENRIQUE MORALES AVILA-
dc.creatorGUILLERMINA FERRO FLORES-
dc.creatorCLARA LETICIA SANTOS CUEVAS-
dc.creatorLAURA MELENDEZ ALAFORT-
dc.creatorROSA MAYDELID TRUJILLO NOLASCO-
dc.creatorBLANCA ELI OCAMPO GARCIA-
dc.date2019-08-01-
dc.date.accessioned2022-04-21T06:01:58Z-
dc.date.available2022-04-21T06:01:58Z-
dc.identifierhttp://hdl.handle.net/20.500.11799/105353-
dc.identifier.urihttp://ri.uaemex.mx/handle20.500.11799/105353-
dc.descriptionThe gastrin-releasing peptide receptor (GRPr) is overexpressed in>75% of breast cancers. 177Lu-Bombesin (177Lu-BN) has demonstrated the ability to target GRPr and facilitate efficient delivery of therapeutic radiation doses to malignant cells. Poly(D,L‑lactide‑co‑glycolide) acid (PLGA) nanoparticles can work as smart drug controlled- release systems activated through pH changes. Considering that paclitaxel (PTX) is a first-line drug for cancer treatment, this work aimed to synthesize and chemically characterize a novel polymeric PTX-loaded nanosystem with grafted 177Lu-BN and to evaluate its performance as a targeted controlled-release nanomedicine for concomitant radiotherapy and chemotherapy of breast cancer. PLGA(PTX) nanoparticles were synthesized using the single emulsification-solvent evaporation method with PVA as a stabilizer in the presence of PTX. Thereafter, the activation of PLGA carboxylic groups for BN attachment through the Lys1-amine group was performed. Results of the chemical characterization by FT-IR, DLS, HPLC and SEM/TEM demonstrated the successful synthesis of BN-PLGA(PTX) with a hydrodynamic diameter of 163.54 ± 33.25 nm. The entrapment efficiency of paclitaxel was 92.8 ± 3.6%. The nanosystem showed an adequate controlled release of the anticancer drug, which increased significantly due to the pH change from neutral (pH=7.4) to acidic conditions (pH=5.3). After labeling with 177Lu and purification by ultrafiltration, 177Lu-BN-PLGA(PTX) was obtained with a radiochemical purity of 99 ± 1%. In vitro and in vivo studies using MDA-MB-231 breast cancer cells (GRPr-positive) demonstrated a 177Lu-BNPLGA( PTX) specific uptake and a significantly higher cytotoxic effect for the radiolabeled nanosystem than the unlabeled BN-PLGA(PTX) nanoparticles. Using a pulmonary micrometastasis MDA-MB-231 model, the added value of 177Lu-BN-PLGA(PTX) for tumor imaging was confirmed. The 177Lu-BN-PLGA(PTX) nanomedicine is suitable as a targeted paclitaxel delivery system with concomitant radiotherapeutic effect for the treatment of GRPr-positive breast cancer.-
dc.descriptionThis study was partially supported by the National Council of Science and Technology (CONACyT-CB-A1S38087) and the International Atomic Energy Agency (CRP-F22064, Contract 18358). It was carried out as part of the activities of the “Laboratorio Nacional de Investigación y Desarrollo de Radiofármacos, CONACyT.-
dc.languageeng-
dc.publisherMaterials Science & Engineering C-
dc.relation10.1016/j.msec.2019.110043-
dc.rightsinfo:eu-repo/semantics/openAccess-
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0-
dc.source0928-4931-
dc.subjectRadiotherapy-
dc.subjectTargeted therapy-
dc.subjectSmart nanoparticles-
dc.subjectDrug delivery-
dc.subjectCancer-
dc.subjectConcomitant cancer treatment-
dc.subjectinfo:eu-repo/classification/cti/2-
dc.title177Lu-Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancer-
dc.typearticle-
dc.audiencestudents-
dc.audienceresearchers-
item.grantfulltextnone-
item.fulltextNo Fulltext-
Appears in Collections:Producción
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.